Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Weishi Chen¹, Pavel Mozgunov¹, Jimmy Mullaert^2,3,4

¹MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.

Pharmaceutical Statistics

|June 18, 2026

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.

Gynecologic oncology·2026

Same author

HydrOcortisone and fludRocortisoNe for critical ILLness-related corticosteroid insufficiency (HORNbILL): study protocol for a multicentre randomised placebo-controlled trial.

BMJ open·2026

Same author

A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection.

The Journal of antimicrobial chemotherapy·2026

Same author

An evaluation of designs for Phase I/IIa dose-finding studies in Tuberculosis.

Statistical methods in medical research·2026

Same author

On the Interplay Between Prior Weight and Variance of the Robustification Component in Robust Mixture Prior Bayesian Dynamic Borrowing Approach.

Statistics in medicine·2026

Same author

Computationally Efficient Approach to Operational Prior Specification in Phase I Clinical Trials.

Statistics in medicine·2026

Same journal

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026

Same journal

Harmonic Fowlkes-Mallows Index for Medical Diagnostics Tests and Optimal Cut-Off Point Selection of Binary Diseases.

Pharmaceutical statistics·2026

Same journal

Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints.

Pharmaceutical statistics·2026

Same journal

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026

Same journal

Will the Pharmaceutical Industry Need Statisticians in an AI World?

Pharmaceutical statistics·2026

Same journal

A Knowledge Base of Designs and Statistical Methods for Adaptive Clinical Dose-Finding Trials.

Pharmaceutical statistics·2026

See all related articles

This study introduces a new clinical trial design for Chimeric Antigen Receptor (CAR)-T cell therapy. It accurately identifies the optimal dose by using both toxicity and CAR-T cell activity, improving treatment selection.

Area of Science:

Immunotherapy
Oncology
Clinical Trial Design

Background:

Chimeric Antigen Receptor (CAR)-T cell therapy has transformed lymphoma and leukemia treatment, offering higher survival rates and lower toxicity.
Traditional Phase I trial designs struggle to determine the optimal dose (OD) for CAR-T cells due to a lack of dose-limiting toxicity (DLT) and unclear dose-effect relationships.

Purpose of the Study:

To propose a novel early-phase dose-finding design for CAR-T cell therapy.
To accurately select the optimal dose (OD) by integrating both toxicity and CAR-T cell activity endpoints.

Main Methods:

Utilized serial peripheral blood samples to measure CAR-T cell expansion over time as a sensitive indicator of activity.
Employed a Bi-Exponential model within a Bayesian framework to analyze repeated cell count measures.

Keywords:

CAR‐T cells dose finding phase I clinical trials

More Related Videos

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: Jun 19, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Considered three activity criteria: cell counts at specific time points, duration of cell persistence, and area under the cell-expansion curve.

Main Results:

The proposed design demonstrated high accuracy in selecting the optimal dose (OD), even with small sample sizes.
Incorporating CAR-T cell expansion data provides a more sensitive measure of activity compared to traditional short-term clinical responses.
The Bi-Exponential model effectively captures diverse CAR-T cell expansion dynamics.

Conclusions:

The novel dose-finding design enhances the precision of optimal dose selection for CAR-T cell therapies.
This approach addresses limitations of traditional trial designs in the context of novel immunotherapies.
Accurate dose selection is crucial for maximizing efficacy and safety in CAR-T cell treatment.